Displaying 1321 - 1340 of 1557
FTC Staff Opposes Alaska Proposal to Allow Physician Collective Bargaining
Announced Actions for January 9, 2002
In re: Buspirone Antitrust Litigation MDL
In re: First Databank Antitrust Litigation
Non-profit Institutions Act Covers Pharmaceuticals Dispensed to Retired Employees, FTC Staff Advises
Hearst Corp. To Disgorge $19 Million and Divest Business to Facts and Comparisons to Settle FTC Complaint
Hearst Trust, The, The Hearst Corporation, and First DataBank, Inc.
The Commission negotiated an agreement with The Hearst Corporation (Hearst) to settle a permanent injunction action filed by the FTC alleging that Hearst failed to provide documents required by premerger notification law and then consummated a merger that monopolized the integrated drug information database market. Under the terms of the order, Hearst divested the Medi-Span business to Lippincott Williams & Wilkins, Inc. , a subsidiary of Wolters Kluwer, n.v., disgorged $19 million in profits, and to complied with certain other obligations.
Statement of Susan A. Creighton, Deputy Director, Bureau of Competition Regarding FTC Settlement with Hearst Corporation
Staff Summary of Federal Trade Commission Activities Affecting Older Americans: January 1999-August 2001: A Commission Staff Report to the United States Senate Special Committee on Aging
Prepared Statement of the Federal Trade Commission On Competition in the Pharmaceutical Marketplace
Antitrust Issues in the Settlement of Pharmaceutical Patent Disputes, Part II
Hoechst Marion Roussel, Inc.; Carderm Capital L.P.; and Andrx Corporation
A consent order settled allegations in an administrative complaint that charged that Hoechst agreed to pay Andrx Corporation millions of dollars not to market and distribute a generic version of Hoechst’s branded Cardizem CD, a once-a-day diltiazem drug product used in the treatment of hypertension and angina. The consent order prohibits the companies from entering into agreements designed to restrict the entry of generic competitors in an attempt to monopolize relevant markets .
Announced Actions for April 30, 2001
Alaska Healthcare Network, Inc.
An association of 86 physicians practicing in the Fairbanks, Alaska area settled charges that the Alaskan Healthcare Network illegally formulated a fee schedule based on its members’ current prices for use in negotiations with third-party payers in an effort to obtain higher prices for medical services.
FTC Charges Hearst Trust with Acquiring Monopoly in Vital Drug Information Market
Consent Agreement Resolves Complaint Against Pharmaceutical Companies Hoechst Marion Roussel, Inc. and Andrx Corp.
FTC Charges Schering-Plough over Allegedly Anticompetitive Agreements with Two Other Drug Manufacturers
FTC Dismisses Complaint Against California Dental Association
VISX, Inc.orporated
On June 4, 1999 an administrative law judge dismissed charges against VISX, a key developer of laser eye surgery equipment and technology, known as photorefractive keratectomy (PRK). According to the 1998 administrative complaint., VISX and Summit Technology, the only two firms legally able to market equipment for PRK, placed their competing patents in a patent pool and shared the proceeds each and every time a Summit or VISX laser was used. The administrative law judge also dismissed charges that VISX acquired a key patent by inequitable conduct and fraud on the U.S. Patent and Trademark Office, ruling that complaint counsel failed to present evidence that an act of fraud was committed since information was not willfully withheld from the patent office. A final order settled the price fixing allegations in the 1998 complaint. On February 7, 2001, the Commission dismissed its complaint after the U.S. patent and Trademark Office issued a Reexamination Certificate of U.S. Patent No. 5,108,388.
Displaying 1321 - 1340 of 1557